## **PCT**

# WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup>:

A61K 38/19, 35/28

(11) International Publication Number: WO 96/40218

A1

(43) International Publication Date: 19 December 1996 (19.12.96)

(21) International Application Number: PCT/US96/07880

(22) International Filing Date: 29 May 1996 (29.05.96)

(30) Priority Data: 08/482,212 7 June 1995 (07.06.95) US

(71) Applicant: ZYMOGENETICS, INC. [US/US]; 1201 Eastlake Avenue East, Seattle, WA 98102 (US).

(72) Inventors: FIBBE, Willem, E.; Veldhorststraat 9, NL-2161 EP Lisse (NL). GROSSMANN, Angelika; 2809 N.E. 60th, Seattle, WA 98115 (US).


(74) Agent: PARKER, Gary, E.; ZymoGenetics, Inc., 1201 Eastlake Avenue East, Seattle, WA 98102 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

#### **Published**

With international search report.

(54) Title: METHODS FOR INCREASING HEMATOPOIETIC CELLS



#### (57) Abstract

Methods for increasing hematopoietic cells, including platelets and erythrocytes, in patients receiving bone marrow or peripheral blood stem cell transplants are disclosed. The methods comprise administering to a donor an amount of thrombopoietin sufficient to stimulate proliferation of cells of the myeloid lineage, collecting cells from the donor, and administering the collected cells to a recipient patient. The recipient patient may be treated with additional thrombopoietin. The methods are useful within allogeneic and autologous transplantation procedures.

## FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
ΑT	Austria	GE	Georgia	MX	Mexico
ΑU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	ΙE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgystan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic	SD	Sudan
CF	Central African Republic		of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SG	
CH	Switzerland	KZ	Kazakhstan	. SI	Singapore Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	
CM	Cameroon	LK	Sri Lanka	SN	Slovakia
CN	China	LR	Liberia	SZ	Senegal
CS	Czechoslovakia	LT	Lithuania	TD	Swaziland
CZ	Czech Republic	LU	Luxembourg	TG	Chad
DE	Germany	LV	Latvia		Togo
DK	Denmark	MC	Monaco	TJ TT	Tajikistan
EE	Estonia	MD	Republic of Moldova	UA	Trinidad and Tobago
ES	Spain	MG	Madagascar		Ukraine
FI	Finland	ML	Mali	UG	Uganda
FR	France	MN	Mongolia	US	United States of America
GA	Gabon	MR	Mauritania	UZ	Uzbekistan
		MIK	Mauritailla	VN	Viet Nam

#### Description

5 METHODS FOR INCREASING HEMATOPOIETIC CELLS

### Background of the Invention

Hematopoiesis is the process by which blood cells develop and differentiate from pluripotent stem 10 cells in the bone marrow. This process involves a complex interplay of polypeptide growth factors (cytokines) acting membrane-bound receptors on their target Cytokine action results in cellular proliferation and differentiation, with a response to a particular cytokine 15 often lineage-specific and/or stage-specific. being Development of a single cell type, such as a platelet, from a stem cell may require the coordinated action of a plurality of cytokines acting in the proper sequence.

It was hypothesized for many years that the 20 production of platelets may be regulated by specific humoral factors. Early experiments had shown that plasma or urine of thrombocytopenic animals contains an activity promotes megakaryocytic colony formation increases the size megakaryocytes. of marrow This 25 activity is referred to in the literature as "thrombopoietin" (recently reviewed by McDonald, Exp. <u>Hematol.</u> <u>16</u>:201-205, 1988 and McDonald, Am. J. Ped. <u>Hematol. Oncol.</u> <u>14</u>:8-21, 1992). The low concentration of this activity and the lack of suitable bioassays long 30 hampered the purification and characterization of the protein. Thrombopoietin has now been produced using genetically engineered cultured cells. See, de Sauvage et Nature 369:533-538, 1994; Lok et al., 369:565-568, 1994; Kaushansky et al., Nature 369:568-571, 1994; and Bartley et al., Cell 77:1117-1124, 1994. 35

Thrombopoietin has been shown to increase platelet numbers in normal (Lok et al., ibid.) and

thrombocytopenic (Sprugel et al., <u>Blood</u> <u>84</u> (10 Suppl. 1):242a, 1994) animals, and to stimulate production of erythrocytes (Kaushansky et al., <u>J. Clin. Invest.</u>, In vitro, TPO enhances survival and proliferation press). CD34+ cells destined to become megakaryocytes (Papayannopoulou et al., <u>Blood</u> <u>84</u> (10 Suppl. 1):324a, 1994).

Although the cloning and characterization of TPO now permits investigation of its clinical use stimulating thrombopoiesis, thrombocytopenia and anemia 10 remain as significant clinical problems, such connection with chemotherapy and radiation therapy cancer patients. There remains a particular need for methods of stimulating platelet production in patients receiving bone marrow transplants and peripheral blood 15 stem cell transplants, including autologous transplants. There also remains a need for stimulating erythrocyte The present invention provides therapeutic production. methods that address these needs, and provides other, 20 related advantages.

#### Summary of the Invention

25

present invention provides methods for increasing hematopoietic cells in a recipient patient in need of such increase. The methods comprise the steps of (a) administering to a donor an amount of thrombopoietin (TPO) sufficient to stimulate proliferation of cells of the myeloid lineage in the donor; (b) collecting cells from the donor, wherein the cells are bone marrow cells or peripheral blood stem cells; and (c) administering the bone marrow cells or peripheral blood stem cells to a recipient patient. The donor and recipient may be different individuals or the same individual. Within one embodiment of the invention, the recipient patient has been treated with chemotherapy or radiation therapy. 35 Within another embodiment, after or concurrently with administering the bone marrow cells or peripheral blood

stem cells, an amount of TPO sufficient to enhance platelet recovery or erythrocyte recovery is administered to the recipient patient.

Within another aspect, the present invention provides methods of preparing cells for transplantation comprising administering to a donor an amount of TPO sufficient to stimulate proliferation of cells of the meeloid lineage in the donor, and collecting cells from the donor, wherein the cells are bone marrow cells or peripheral blood stem cells.

Within a third aspect, the present invention provides a method of stimulating platelet recovery or erythrocyte recovery in a patient receiving chemotherapy or radiation therapy comprising (a) administering to the patient of an amount TPO sufficient to proliferation of cells of the myeloid lineage in the patient; (b) collecting bone marrow cells or peripheral blood stem cells from the patient prior to chemotherapy or radiation therapy; and (c) returning the collected cells to the patient subsequent to chemotherapy or radiation therapy. Within one embodiment this method further comprises administering to the patient, after concurrently with returning the collected cells, an amount sufficient to enhance platelet recovery or of TPO erythrocyte recovery.

These and other aspects of the invention will become evident upon reference to the following detailed description and the attached drawings.

## 30 Brief Description of the Drawings

15

20

25

Fig. 1 illustrates the effect of transplantation of bone marrow cells from TPO- or vehicle-treated donor mice on platelet counts in recipient animals. In one experiment recipients of TPO-treated marrow were also treated with TPO (20 kU/day i.p.). Data are presented as means of 10-20 mice in two experiments. \*, p<0.05; \*\*, p<0.01.

Fig. 2 illustrates the effect of transplantation of bone marrow cells from TPO- or vehicle-treated donor mice on erythrocyte counts in recipient animals. Data are expressed as mean of 20 mice in two experiments. \*, 5 p<0.05; \*\*, p<0.005.

Fig. 3 illustrates platelet recovery in mice receiving marrow transplants from TPO- or vehicle-treated donors, with or without post-transplant TPO treatment.

## 10 Detailed Description of the Invention

25

30

The term "stem cell" is used herein to denote pluripotent hematopoietic stem cells and myeloid progenitor cells.

The term "transplantation" is used herein to

denote the process of removing cells from a donor and
subsequently administering the cells to a recipient. The
term encompasses both allogeneic transplantation, wherein
the donor and recipient are different individuals of the
same species; and autologous transplantation, wherein the

donor and recipient are the same individual.

The term "increasing hematopoietic cells" is used herein to denote the restoration or enhanced recovery of hematopoietic cell levels following their ablation, such as ablation resulting from disease or therapeutic intervention.

The term "thrombopoietin" encompasses proteins characterized by their ability to specifically bind to MPL receptor from the same species and to stimulate platelet production in vivo. In normal test animals, TPO is able to increase platelet levels by 100% or more within 10 days after beginning daily administration. A representative human TPO cDNA sequence is shown in SEQ ID NO: 1, and the corresponding amino acid sequence is shown in SEQ ID NO: 2. Analytical and experimental evidence indicates that the mature protein begins at residue Ser-22. Those skilled in the art will recognize that the illustrated sequences correspond to a single allele of the human TPO

gene, and that allelic variation is expected to exist. Allelic variants include those containing silent mutations and those in which mutations result in amino acid sequence It will also be evident that one skilled in the changes. could create additional variants, engineering sites that would facilitate manipulation of the nucleotide sequence using alternative codons, bv substitution of codons to produce conservative changes in amino acid sequence, etc. The allelic use of 10 engineered variant TPOs is contemplated by the present In addition, amino-terminal TPO polypeptides of about 150 amino acids or more in length are known to be active (de Sauvage et al., ibid.; Bartley et al., ibid.; co-pending, commonly assigned U.S. Patent application 15 Serial No. 08/346,999), and the use of such truncated forms of TPO is within the scope of the present invention. Thrombopoietins from non-human species have been disclosed in the scientific literature (Lok et al., ibid.: Sauvage et al., ibid; Bartley et al., ibid.).

5

20 present invention provides The methods increasing hematopoietic cells in patients, particularly patients undergoing radiation therapy and/or chemotherapy, such as in the treatment of cancer. Such therapies kill dividing progenitor cells in the marrow and peripheral 25 blood, limiting therapy and often requiring transfusions to restore circulating levels of platelets and other blood cells. Of particular interest are those patients receiving bone marrow and/or peripheral blood stem cell transplants following radiation therapy and suffering from congenital metabolic defects necessitating bone marrow transplant. Among these indications are bone marrow transplants associated with treatment of breast cancer, leukemia, lymphoma, multiple myeloma and congenital defects such as severe combined immune deficiency, thallasemia, and sickle cell anemia. Peripheral blood stem cell transplantation may

preferred in conditions where a risk of tumor cells in the blood is not present.

Methods for carrying out bone marrow and peripheral blood stem cell transplants are known in the For a review, see Snyder et al., "Transfusion Medicine" in Benz and McArthur, eds., Hematology 1994, American Society of Hematology, 96-106, 1994. blood stem cells are collected by leukapheresis according to accepted clinical procedures. Hematopoietic progenitor cells can be selected on the basis of cell surface markers 10 (e.g. CD34), allowing for enrichment of the desired cells and depletion of contaminating tumor cells. The collected cells are stored frozen in a suitable cryoprotectant (e.g. dimethyl sulfoxide, hydroxyethyl starch) until needed. Marrow cells are collected from donors by bone puncture 15 under anesthesia. To reduce the volume, the collected marrow is usually processed to separate plasma from the cellular components. Removal of plasma can also eliminate red cell incompatibilities in allogeneic transplantation. 20 The cell fraction can be enriched for mononuclear cells using density gradient techniques or automated separation methods and depleted of T cells using various cytotoxic agents. Collected marrow cells are cryopreserved according to established procedures that include controlled-rate freezing and the use of cryoprotectants. 25 Stem cells are thawed in a warm water bath immediately prior to use to minimize loss associated with thawing. the case of allogeneic transplants, donors and recipients are tissue matched to minimize the risk of graft-versus-3.0 host disease.

An increase in hematopoietic cells results from transplantation into a recipient patient of stem cells, particularly cells of the myeloid lineage, including CD34+ stem cells and cells derived from CD34+ stem cells. Of particular interest are cells in the megakaryocyte and erythrocyte lineages, which reconstitute the recipient's platelet and erythrocyte populations, respectively.

35

WO 96/40218

15

PCT/US96/07880

Within the present invention, a donor treated, prior to donation of marrow or peripheral blood cells, with TPO in an amount sufficient to stimulate proliferation of cells of the myeloid lineage. amout will generally be in the range of 0.5 lg/kg/day to 40 lg/kg/day, preferably 1 lg/kg/day to 20 lg/kg/day. Treatment of the donor will be carried out for a period of from one to several days, preferably about 2-5 days, during a period of from 3 days to 2 weeks prior to harvesting of bone marrow or peripheral blood stem cells. It is preferred to treat the donor during a period of five to ten days prior to harvesting of cells. The increase in CD34+ stem cells and other cells of the myeloid lineage in the donor will be manifested by improved recovery of platelet and/or erythrocyte levels in the transplant recipient.

7

Within one embodiment of the invention, recipient is treated with TPO after transplantation to further enhance platelet recovery. It has been found that post-transplantation treatment with TPO improves survival 20 of lethally-irradiated test animals given bone marrow from TPO-treated donors. "An amount of thrombopoietin sufficient to enhance platelet recovery" is that amount that produces a statistically significant reduction in recovery of normal platelet levels 25 statistically significant increase in platelet count as compared to untreated patients. Doses of TPO used in post-transplantation treatment will generally be in the range of 0.5 lg/kg/day to 40 lg/kg/day administered for from about 3 to about 20 days. 30 In general, patients receiving bone marrow transplants will require longer post-transplantation treatment than those receiving peripheral blood stem cell transplants.

For use within the present invention, TPO can be prepared using genetically engineered, cultured cells according to methods generally known in the art. To summarize these methods, a DNA molecule encoding TPO is

joined to other DNA sequences which provide for maintenance and transcription in a host cell. The resulting expression vector is inserted into the host cell, and the resulting "transformed" or "transfected" 5 cells are cultured in a suitable nutrient medium. hamster kidney (BHK) cells are a preferred host. preferred to engineer the cells to secrete the TPO into the medium, although TPO can be recovered from cell lysates and processed in vitro to yield active protein. See, in general, de Sauvage et al., ibid.; Lok et al., 10 ibid.; Kaushansky et al., Nature 369:568-571, Wendling et al., Nature 369:571-574, 1994; Bartley et al., ibid.; and co-pending, commonly assigned U.S. Patent Applications Serial 08/366,859 No. and Serial No. 08/347,029, which are incorporated herein by reference in 15 their entirety.

TPO may be purified from cell-conditioned culture media by a combination of chromatographic and other techniques, including direct capture on a dye-ligand affinity matrix and ion-exchange chromatography. Contaminating proteins may be removed by adsorption to hydroxyapatite.

20

For pharmaceutical use, TPO is formulated for parenteral, particularly intravenous or subcutaneous. delivery according to conventional methods. 25 Intravenous administration will be by bolus injection or infusion over a typical period of one to several hours. In general, pharmaceutical formulations will include a hematopoietic protein in combination with a pharmaceutically acceptable vehicle, such as saline, buffered saline, 5% dextrose in water or the like. Formulations may further include one or more excipients, preservatives, solubilizers, buffering agents (e.g. phosphate buffer), albumin or a non-ionic detergent to prevent protein loss on vial surfaces, etc. In addition, TPO may be combined with other cytokines, 35 particularly early-acting cytokines such as factor, IL-3, IL-6, IL-11 or GM-CSF. When utilizing such

a combination therapy, the cytokines may be combined in a single formulation or may be administered in separate formulations. Methods of formulation are well known in the art and are disclosed, for example, in Remington's Pharmaceutical Sciences, Gennaro, ed., Mack Publishing Co., Easton PA, 1990, which is incorporated herein by reference.

The invention is further illustrated by the following, non-limiting examples.

10

## Examples

### Example 1

Mouse thrombopoietin was prepared using transfected baby hamster kidney cells (BHK 570 cells, ATCC 15 CRL 10314). Serum-free medium contained 145 kU/ml of TPO activity, wherein 10 units are defined as the amount of TPO giving half-maximal stimulation in a mitogenesis (3Hthymidine incorporation) assay using transfected with an expression vector encoding the human 20 MPL receptor (Vigon et al., Proc. Natl. Acad. Sci. USA <u>89</u>:5640-5644, 1992) as target cells. BaF3 is interleukin-3 dependent pre-lymphoid cell line derived from murine bone marrow (Palacios and Steinmetz, Cell 41: 727-734, 1985; Mathey-Prevot et al., Mol. Cell. Biol. 6: 4133-4135, 1986). Cells were exposed to test samples in the presence of  $^{3}H$ -thymidine. The amount of  $^{3}H$ -thymidine incorporated into cellular DNA was quantitated comparison to a standard curve of human TPO. Mouse TPO samples were effective in colony forming assays in a range of approximately 100-400 U/ml. In vivo activities were seen in the range of 20-40 kU/day in mice. For in vivo experiments, TPO was diluted to the desired concentration endotoxin-free phosphate-buffered saline (PBS) administered intraperitoneal as orsubcutaneous 35 injections.

Female Balb-C mice (age range 8-12 weeks) were obtained from Broekman B.V. (Someren, The Netherlands) and

fed commercially available rodent chow and provided with acidified water ad libitum. Transplant recipients were maintained in a pathogen-free environment and provided with water containing ciprofloxacin at a concentration of 1 mg/ml, polymyxine-B at 70 lg/ml, and saccharose at 2 g/100 ml.

Recipient mice were placed in a polymethylmetaacetate box and lethally (8.5 Gy) irradiated using a Philips SL 75-5/6 mV linear accelerator (Philips Medical Systems, Best, The Netherlands). 10 Irradiation was divided in two parts in posterior-anterior and anterior-posterior position, at a dose rate of 4 Gy/minute. The mice were transplanted with  $10^5$  bone marrow cells from steady-state Tranplantation was carried out within four donor mice. 15 hours of marrow harvesting. Groups of 5 recipient mice treated with TPO at a dose of 20 intraperitoneally (i.p.) on days 1-5, 3-8 or 3-12 after transplantation. Control animals were transplanted with an equal amount of marrow cells and given saline at 20 similar time intervals after transplantation. In comparison with saline-treated control recipients, TPO administration did not result in accelerated platelet reconstitution. Α dose of 30 kU/day administered subcutaneously (s.c.) on days 1-14 was also ineffective in accelerating platelet recovery. No effects were seen on 25 reconstitution of white blood cells or red blood cells.

In a second set of experiments, donor mice were treated with TPO for five consecutive days at a dose of 20 kU/day i.p. per mouse. At day 5 the mice were sacrificed, and blood, bone marrow and spleens were harvested. White blood cells, red blood cells and platelets were counted on a Sysmex 800 counter (TOA Medical Electronics Company, Kobe, Japan). TPO treatment induced a 2.5-fold increase in the numbers of platelets, but had no effect on the numbers of white blood cells or red blood cells.

Progenitor cell levels were also determined in the TPO-treated donor mice. Bone marrow cells were

harvested by flushing femurs under sterile conditions with RPMI 1640 containing 500 lg/ml penicillin, 250 lg/ml streptomycin, and 2% fetal bovine serum (FBS) (GIBCO BRL, Gaithersburg, MD). Single-cell suspensions of the spleens 5 were prepared by mashing the organs and washing once with RPMI 1640 containing 2% FBS. To determine colony forming CFU-GM were cultured according to published procedures (Fibbe et al., J. Immunol. 148:417, 1992). Briefly, bone marrow cells were cultured in microtiter 10 plates containing  $10^4$  cells/well in semi-solid medium in the presence of murine GM-CSF (1.25 ng/ml). Peripheral blood mononuclear cells and spleen cells were cultured in 3.5 cm dishes containing  $5x10^5$  cells/ml and  $10^6$  cells/ml, respectively. Cells were cultured in a fully humidified 15 atmosphere at 37°C containing 5% CO2. After 6 days of culture the number of colonies (defined as aggregates of >20 cells) were scored using an inverted microscope. The CFU-mix assay was performed in an identical fashion in 3.5 cm dishes in the presence of a combination of 1.25 ng/mlrecombinant murine GM-CSF, 2 U/ml recombinant human EPO, 25 ng/ml recombinant murine IL-3, 5% transferrin, bovine serum albumin, 5%  $10^{-3}$  b-mercaptoethanol, and 7.5% Iscove's modified Dulbecco's medium (IMDM). After 6 to 7 days of culture at 37°C in a fully humidified, 5%  $CO_2$ atmosphere, the number of colony forming cells was scored using an inverted microscope. TPO treatment resulted in increased numbers of colony forming units (CFU) and BFU-Es in the bone marrow or spleen in comparison with salinetreated controls (Table).

5

•	Table	
Do	nor Treatment	
	TPO	<u>Saline</u>
Femur		
Nucleated cells (x10 <sup>6</sup> )	$18.4 \pm 4.7$	19.9 ± 4.3
CFU (x10 <sup>3</sup> )	55.3 ± 12.5*	38.6 ± 5.2
BFU-E (x10 <sup>3</sup> )	$24.0 \pm 4.9$	16.4 ± 2.3
Spleen		
Nucleated cells (x10 <sup>6</sup> )	$71.8 \pm 35.0$	78.4 ± 42.5
CFU (x10 <sup>3</sup> )	27.3 ± 16.9	16.3 ± 11.4
BFU-E (x10 <sup>3</sup> )	$10.2 \pm 2.3$	1.9 ± 0.7
Results are expressed	as absolute c	ell numbers
$(mean \pm S.D., n=7)$ per		
CFU represents the t		_
cultured in the CFU-mix		

Lethally-irradiated recipient animals were transplanted with 10<sup>5</sup> bone marrow cells from donors that had been treated with TPO at a dose of 20 kU/day i.p. for five consecutive days, or from saline-treated control donors. Blood samples were taken after tranplantation from individual recipients every 3 days by tail vein bleeding. No difference in visible bleeding tendency was observed between recipients of TPO-modified or unmodified bone marrow cells.

Cell counts were analyzed using the student's T tests. In the MANOVA analysis, groups were compared with respect to their course over time. The analysis was performed on the log values of the data. Values of <0.05 were considered statistically significant. Curves were compared using the MANOVA test. Results showed that the reconstitution of platelets in recipients of TPO-treated marrow was significantly altered in comparison to control animals transplanted with an equal number of bone marrow cells from saline-treated control donors (Fig. 1). In addition, platelet nadir counts were higher in animals

receiving TPO-treated marrow than those receiving control marrow (88 x  $10^9$  vs. 30 x  $10^9$  at day 12 after transplantation, mean of 20 mice). As shown in Fig. 1, post-transplant treatment with 20 kU/day TPO i.p. on days 1-5 did not result in a further acceleration of platelet reconstitution in mice that received marrow from TPO-treated donors.

In addition to an accelerated reconstitution of platelets, recipients of TPO-modified bone marrow cells also exhibited accelerated reconstitution of erythrocytes 2). The erythrocyte nadir counts were significantly higher in these animals than in controls transplanted with an equal number of unmodified bone marrow cells. Experiments were performed to further substantiate that this effect was due to a direct activity of TPO on erythropoiesis and not related to differences in platelet counts and bleeding tendency. In this experiment recipient animals were not bled until 12 days after transplantation, at which time the recipient mice were sacrificed, and the numbers of bone marrow and bloodderived progenitor cells were assessed. Recipients of TPO-modified bone marrow cells had a higher number of BFU-E colonies/femur (770  $\pm$  386 vs 422  $\pm$  320, mean  $\pm$  SD, n=5) and higher reticulocytes in the blood (44% vs. 8%, mean of 5 mice) than controls transplanted with an equal number of 25 unmodified bone marrow cells, although these differences did not reach statistical significance. Post-transplant treatement with TPO did not result in further acceleration of erythrocyte reconstitution at the doses tested.

30

#### Example 2

A second experiment was carried out to compare platelet counts in lethally irradiated mice receiving marrow from TPO-treated or non-treated donors, and to determine the effect of post-transplantation TPO treatment of the recipient animals.

B6D2 F1 mice were obtained from Taconic (Germantown, NY) and housed under specific pathogen-free conditions. The mice were housed five per cage and received acidified water and food ad libitum. Forty female mice were used as recipients, and five male mice were used as donors.

Recombinant human TPO was prepared using transfected BHK 570 cells. The major molecular species was a 70 kD band. The preparation had a specific activity of 5641 U/lg. The protein was made up in 29 mM potassium phosphate buffer, pH 6.0, containing 0.05% polysorbate 80 and 0.13 M NaCl and stored frozen in 20 kU aliquots. TPO and vehicle solutions were thawed directly before use and were injected into mice once daily, subcutaneously.

15 Two donor mice were each treated with 20 kU of TPO per day for four days, then sacrificed by cervical dislocation on the fifth day. Control donors were treated with vehicle only. Femora were taken out aseptically, and marrow was flushed out with Ham's F12 Hutchinson Cancer Research Center, Seattle, WA) containing 20 fetal bovine serum by inserting a 25 q. connected to a syringe. The cell suspension was flushed twice through an 18 g. needle, a 20 g. needle, and a 22 g. needle to produce a single-cell suspension. Nucleated cells were counted in a hemocytometer.

On day -2, recipient mice were exposed to 1200 cGy total body irradiation from a 137Cs source (Gammacell 40 Irradiator, Atomic Energy of Canada Radiochemical Company, Kanata, Canada). Bone marrow transplants were performed two to four hours after irradiation. Twenty mice received bone marrow (1x10<sup>5</sup> cells) from TPO-treated donors, and twenty mice received 1x10<sup>5</sup> cells from vehicletreated donors. Recipients were treated with TPO (20 kU/day) beginning on day 1 (2 days after transplantation) and continuing for 14 days.

Mice were bled from the retroorbital sinus under ether anesthesia. Fifty ll blood samples were collected

in heparinized micropipettes (VWR Scientific, Seattle, WA) and dripped into microtainer tubes with EDTA (Becton Dickinson, San Jose, CA). Blood was also dripped onto glass slides, and smears were prepared. Blood was analyzed in a Cell Dyn 3500 hematology analyzer (Abbott, Santa Clara, CA). Hematocrit, RBC counts, WBC counts and platelet counts were determined.

In mice receiving marrow from control donors, platelet counts dropped on day 8 to low levels (below 6% of normal) and started to recover in TPO-treated and 10 control animals on day 12 (Fig. 3). There was difference between the two groups in platelet recovery. However, in the vehicle-treated controls only 3 of 10 animals survived, whereas in the TPO-treated group 7 of 9 15 animals survived. Death was related to hemorrhage. Standard deviations were large within the TPO-treated group because some animals with very low platelet counts were able to survive.

Mice receiving marrow from TPO-treated donors
also had platelet numbers that were below 6% of normal on
day 8. Animals that were treated with TPO for 14 days
had, in general, a faster recovery in platelet counts.
Eight of nine TPO-treated animals survived, whereas only
four of nine vehicle-treated mice survived. RBCs
recovered faster in mice that received TPO-pretreated bone
marrow and were treated with TPO compared to controls.
There was no influence of TPO treatment on white blood
cell recovery.

From the foregoing, it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

#### SEQUENCE LISTING

#### (1) GENERAL INFORMATION:

(i) APPLICANT: ZymoGenetics, Inc.

1201 Eastlake Avenue East

Seattle

WA USA 98102

- (ii) TITLE OF INVENTION: METHODS FOR INCREASING HEMATOPOIETIC CELLS
  - (iii) NUMBER OF SEQUENCES: 2
    - (iv) CORRESPONDENCE ADDRESS:
      - (A) ADDRESSEE: ZymoGenetics, Inc.
      - (B) STREET: 1201 Eastlake Avenue East
      - (C) CITY: Seattle
      - (D) STATE: WA
      - (E) COUNTRY: USA
      - (F) ZIP: 98102
    - (v) COMPUTER READABLE FORM:
      - (A) MEDIUM TYPE: Floppy disk
      - (B) COMPUTER: IBM PC compatible
      - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
      - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
  - (vi) CURRENT APPLICATION DATA:
    - (A) APPLICATION NUMBER:
    - (B) FILING DATE:
    - (C) CLASSIFICATION:
  - (viii) ATTORNEY/AGENT INFORMATION:
    - (A) NAME: Parker, Gary E
    - (B) REGISTRATION NUMBER: 31-648
    - (C) REFERENCE/DOCKET NUMBER: 95-10
    - (ix) TELECOMMUNICATION INFORMATION:
      - (A) TELEPHONE: 206-442-6600 ext 6673
      - (B) TELEFAX: 206-442-6678
- (2) INFORMATION FOR SEQ ID NO:1:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 1062 base pairs

(B) TYPE: nucleic acid(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

#### (ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..1059

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

ATG GAG CTG ACT GAA TTG CTC CTC GTG GTC ATG CTT CTC CTA ACT GCA 48

Met Glu Leu Thr Glu Leu Leu Val Val Met Leu Leu Thr Ala

1 5 10 15

AGG CTA ACG CTG TCC AGC CCG GCT CCT GCT TGT GAC CTC CGA GTC 96

Arg Leu Thr Leu Ser Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val

20 25 30

CTC AGT AAA CTG CTT CGT GAC TCC CAT GTC CTT CAC AGC AGA CTG AGC 144

Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser

35 40 45

CAG TGC CCA GAG GTT CAC CCT TTG CCT ACA CCT GTC CTG CCT GCT 192

Gln Cys Pro Glu Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala

50 55 60

GTG GAC TTT AGC TTG GGA GAA TGG AAA ACC CAG ATG GAG GAG ACC AAG 240

Val Asp Phe Ser Leu Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Lys

65 70 75

80

GCA CAG GAC ATT CTG GGA GCA GTG ACC CTT CTG CTG GAG GGA GTG ATG 288

Ala Gln Asp Ile Leu Gly Ala Val Thr Leu Leu Glu Gly Val Met

90 95

GCA GGG	GCA		GGA 36	CAA	CTG	GGA	CCC	ACT	TGC	CTC	TCA	TCC	CTC	CTG
Ala Gly	Ala			Gln	Leu	Gly	Pro	Thr	Cys	Leu	Ser	Ser	Leu	Leu
•			100					105					110	
CAG CTC	CTT	TCT	GGA 84	CAG	GTC	CGT	CTC	CTC	CTT	GGG	GCC	CTG	CAG	AGC
	Leu			Gln	Val	Arg	Leu	Leu	Leu	Gly	Ala	Leu	Gln	Ser
		115					120					125		
CTT GAT	GGA		CAG 32	CTT	CCT	CCA	CAG	GGC	AGG	ACC	ACA	GCT	CAC	AAG
	Gly			Leu	Pro	Pro	Gln	Gly	Arg	Thr	Thr	Ala	His	Lys
1105	130					135					140			
CCC GTG	AAT		ATC 80	TTC	CTG	AGC	TTC	CAA	CAC	CTG	CTC	CGA	GGA	AAG
				Phe	Leu	Ser	Phe	Gln	His	Leu	Leu	Arg	Gly	Lys
145 160					150					155				
CGT	TTC	CTG	ATG 28	CTT	GTA	GGA	GGG	TCC	ACC	CTC	TGC	GTC	AGG	CGG
	Phe			Leu	Val	Gly	Gly	Ser	Thr	Leu	Cys	Val	Arg	Arg
ALA				165					170					175
CCA CTG	CCC	ACC 57	ACA	GCT	GTC	CCC	AGC	AGA	ACC	TCT	CTA	GTC	CTC	ACA
	Pro			Ala	Val	Pro	Ser	Arg	Thr	Ser	Leu	Val	Leu	Thr
пец		40	180					185					190	
AAC ACT	GAG	CTC 62		AAC	AGG	ACT	TCT	GGA	TTG	TTG	GAG	ACA	AAC	TTC
	Glu			Asn	Arg	Thr	Ser	Gly	Leu	Leu	Glu	Thr	Asn	Phe
1111		195					200					205		
GCC GGA	TCA	GCC 67		ACT	ACT	GGC	TCT	GGG	CTT	CTG	AAG	TGG	CAG	CAG
	Ser		_	Thr	Thr	Gly	Ser	Gly	Leu	Leu	Lys	Trp	Gln	Gln
OT A	210					215					220			
TTC CTG	AGA	GCC 72		ATT	CCT	GGT	CTG	CTG	AAC	CAA	ACC	TCC	AGG	TCC

Phe Arg Ala Lys Ile Pro Gly Leu Leu Asn Gln Thr Ser Arg Ser Leu 225 230 235 240 GAC CAA ATC CCC GGA TAC CTG AAC AGG ATA CAC GAA CTC TTG AAT Asp Gln Ile Pro Gly Tyr Leu Asn Arg Ile His Glu Leu Leu Asn Gly 245 250 255 ACT CGT GGA CTC TTT CCT GGA CCC TCA CGC AGG ACC CTA GGA GCC 816 Thr Arg Gly Leu Phe Pro Gly Pro Ser Arg Arg Thr Leu Gly Ala Pro 260 265 270 GAC ATT TCC TCA GGA ACA TCA GAC ACA GGC TCC CTG CCA CCC AAC Asp Ile Ser Ser Gly Thr Ser Asp Thr Gly Ser Leu Pro Pro Asn Leu 275 280 285 CAG CCT GGA TAT TCT CCT TCC CCA ACC CAT CCT CCT ACT GGA CAG Gln Pro Gly Tyr Ser Pro Ser Pro Thr His Pro Pro Thr Gly Gln Tyr 290 295 300 ACG CTC TTC CCT CTT CCA CCC ACC TTG CCC ACC CCT GTG GTC CAG 960 Thr Leu Phe Pro Leu Pro Pro Thr Leu Pro Thr Pro Val Val Gln Leu 305 310 315 320 CAC CCC CTG CTT CCT GAC CCT TCT GCT CCA ACG CCC ACC CCT ACC His Pro Leu Leu Pro Asp Pro Ser Ala Pro Thr Pro Thr Ser 325 330 CCT CTT CTA AAC ACA TCC TAC ACC CAC TCC CAG AAT CTG TCT CAG GAA 1056 Pro Leu Leu Asn Thr Ser Tyr Thr His Ser Gln Asn Leu Ser Gln Glu 340 345 350 GGG TAA 1062 Gly

(2) INFORMATION FOR SEQ ID NO:2:

		(i)	SEQU (A (B	L) LE	NGTH PE:		3 am 10 ac	nino cid	3: acid	ls				
	(	ii)	MOLE	CULE	TYF	E: p	rote	in						
	(	xi)	SEQU	ENCE	DES	CRIP	TION	: SE	Q ID	NO:	2:			
Ата		Leu	Thr		Leu	Leu	Leu	Val	Val	Met	Leu	Leu	Leu	Thr
1				5					10					15
Arg Val	Leu	Thr	Leu	Ser	Ser	Pro	Ala	Pro	Pro	Ala	Cys	Asp	Leu	Arg
			20					25					30	
Leu Ser	Ser	Lys	Leu	Leu	Arg	Asp	Ser	His	Val	Leu	His	Ser	Arg	Leu
		35					40					45		
Gln Ala	Cys	Pro	Glu	Val	His	Pro	Leu	Pro	Thr	Pro	Val	Leu	Leu	Pro
	50					55					60			
Val Lys	Asp	Phe	Ser	Leu	Gly	Glu	Trp	Lys	Thr	Gln	Met	Glu	Glu	Thr
65 80					70					75				
Ala Met	Gln	Asp	Ile	Leu	Gly	Ala	Val	Thr	Leu	Leu	Leu	Glu	Gly	Val
				85					90					95
Ala Gly	Ala	Arg	Gly	Gln	Leu	Gly	Pro	Thr	Cys	Leu	Ser	Ser	Leu	Leu
1			100					105					110	
Gln Leu	Leu	Ser	Gly	Gln	Val	Arg	Leu	Leu	Leu	Gly	Ala	Leu	Gln	Ser
		115		•.			120					125		
Leu Asp	Gly	Thr	Gln	Leu	Pro	Pro	Gln	Gly	Arg	Thr	Thr	Ala	His	Lys
nap	130					135					140			

Pro Val 145 160	Asn	Ala	Ile	Phe	Leu 150	Ser	Phe	Gln	His	Leu 155	Leu	Arg	Gly	Lys
Arg Ala	Phe	Leu	Met	Leu	Val	Gly	Gly	Ser	Thr	Leu	Cys	Val	Arg	Arg
				165					170					175
Pro Leu	Pro	Thr		Ala	Val	Pro	Ser		Thr	Ser	Leu	Val	Leu	Thr
			180					185					190	
Asn Thr	Glu	Leu	Pro	Asn	Arg	Thr	Ser	Gly	Leu	Leu	Glu	Thr	Asn	Phe
		195					200					205		
Ala Gly	Ser	Ala	Arg	Thr	Thr	Gly	Ser	Gly	Leu	Leu	Lys	Trp	Gln	Gln
<b>4-</b> 1	210					215					220			
Phe Leu	Arg	Ala	Lys	Ile	Pro	Gly	Leu	Leu	Asn	Gln	Thr	Ser	Arg	Ser
225 240					230					235				
Asp Gly	Gln	Ile	Pro	Gly	Tyr	Leu	Asn	Arg	Ile	His	Glu	Leu	Leu	Asn
Cly				245					250					255
Thr Pro	Arg	Gly	Leu	Phe	Pro	Gly	Pro	Ser	Arg	Arg	Thr	Leu	Gly	Ala
FIO			260					265					270	
Asp Leu	Ile	Ser	Ser	Gly	Thr	Ser	Asp	Thr	Gly	Ser	Leu	Pro	Pro	Asn
пеп		275					280					285		
Gln	Pro	Gly	Tyr	Ser	Pro	Ser	Pro	Thr	His	Pro	Pro	Thr	Gly	Gln
Tyr	290					295					300			
Thr	Leu	Phe	Pro	Leu	Pro	Pro	Thr	Leu	Pro	Thr	Pro	Val	Val	Gln
Leu 305 320					310					315				
His	Pro	Leu	Leu	Pro	Asp	Pro	Ser	Ala	Pro	Thr	Pro	Thr	Pro	Thr
Ser				325					330					335

Pro Leu Leu Asn Thr Ser Tyr Thr His Ser Gln Asn Leu Ser Gln Glu 340 345 345

Gly

#### Claims

1. A method for increasing hematopoietic cells in a recipient patient in need of such increase comprising:

administering to a donor an amount of thrombopoietin (TPO) sufficient to stimulate proliferation of cells of the myeloid lineage in the donor;

collecting cells from the donor, wherein the cells are bone marrow cells or peripheral blood stem cells;

administering the bone marrow cells or peripheral blood stem cells to a recipient patient.

- 2. A method according to claim 1 wherein the recipient patient has been treated with chemotherapy or radiation therapy.
- 3. A method according to claim 1 wherein the donor and the recipient patient are the same individual.
- 4. A method according to claim 3 wherein the recipient patient is treated with chemotherapy or radiation between the collecting and second administering steps.
- 5. A method according to claim 1 wherein the cells are bone marrow cells.
- 6. A method according to claim 1 wherein the cells are peripheral blood stem cells.
- 7. A method according to claim 1 further comprising administering to the recipient patient, after or concurrently with administering the bone marrow cells or peripheral blood stem cells, an amount of

thrombopoietin sufficient to enhance platelet recovery or erythrocyte recovery.

- 8. A method according to claim 1 wherein the TPO is human TPO.
- 9. A method of preparing cells for transplantation comprising:

administering to a donor an amount of thrombopoietin (TPO) sufficient to stimulate proliferation of cells of the myeloid lineage in the donor;

collecting cells from the donor, wherein the cells are bone marrow cells or peripheral blood stem cells.

- 10. A method according to claim 9 wherein the TPO is human TPO.
- 11. A method according to claim 9 wherein the cells are bone marrow cells.
- 12. A method according to claim 9 wherein the cells are peripheral blood stem cells.
- 13. A method of stimulating platelet or erythrocyte recovery in a patient receiving chemotherapy or radiation therapy comprising:


administering to the patient an amount of TPO sufficient to stimulate proliferation of cells of the myeloid lineage in the patient;

collecting bone marrow cells or peripheral blood stem cells from the patient prior to chemotherapy or radiation therapy; and

returning the collected cells to the patient subsequent to chemotherapy or radiation therapy.

14. A method according to claim 13 further comprising administering to the patient, after or concurrently with returning the collected cells, an amount of thrombopoietin sufficient to enhance platelet recovery or erythrocyte recovery.

- 15. A method according to claim 13 wherein the TPO is human TPO.
- 16. A method according to claim 13 wherein the cells are bone marrow cells.
- 17. A method according to claim 13 wherein the cells are peripheral blood stem cells.







FIG. 2



## INTERNATIONAL SEARCH REPORT

Internal Application No

			101/03 90/0/000			
A. CLASS IPC 6	IFICATION OF SUBJECT MATTER A61K38/19 A61K35/28					
According t	to International Patent Classification (IPC) or to both national class	sification and IPC				
	SEARCHED					
Minimum d IPC 6	locumentation searched (classification system followed by classification A61K C07K	ation symbols)				
Documenta	tion searched other than minimum documentation to the extent that	t such documents are inc	luded in the fields searched			
Electronic d	lata base consulted during the international search (name of data ba	ase and, where practical,	search terms used)			
C. DOCUM	MENTS CONSIDERED TO BE RELEVANT					
Category *	Citation of document, with indication, where appropriate, of the	relevant passages	Relevant to claim No.			
Х	NATURE, vol. 369, 1994, LONDON GB,		1-17			
	pages 519-520, XP002013270 DONALD METCALF: "Thrombopoietin see page 520, columns 2-3	-at last"				
Α .	LANCET THE, vol. 339, 1992, LONDON GB, pages 640-644, XP002013271 SHERIDAN, W.P. ET AL: "Effect of peripheral-blood progenitor cell mobilised by filgrastim (G-CSF) platelet recovery after high-dose chemotherapy" see the whole document	1-17				
		-/				
X Furti	her documents are listed in the continuation of box C.	Patent family i	members are listed in annex.			
'A' docume conside 'E' earlier filing of 'L' docume which citation 'O' docume other r 'P' docume later the	ent which may throw doubts on priority claim(s) or is cited to establish the publication date of another in or other special reason (as specified) ent referring to an oral disclosure, use, exhibition or	or priority date an cited to understand invention  "X" document of partic cannot be consider involve an invention  "Y" document of partic cannot be consider document is comb ments, such combining the art.  "&" document member	chished after the international filing date and not in conflict with the application but did the principle or theory underlying the cultar relevance; the claimed invention red novel or cannot be considered to we step when the document is taken alone cultar relevance; the claimed invention red to involve an inventive step when the internation or more other such document with one or more other such document being obvious to a person skilled of the same patent family			
1:	3 September 1996		.09.1996			
Name and n	nailing address of the ISA  European Patent Office, P.B. 5818 Patentlaan 2  NL - 2280 HV Rijswijk  Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  Fax: (+ 31-70) 340-3016	Authorized officer  Fernandez y Branas, F				

Form PCT/ISA/218 (second sheet) (July 1992)

• 1

# INTERNATIONAL SEARCH REPORT

Inter nal Application No
PC1/US 96/07880

C (C:	POCUMENTO CONTROL CONT	PC1/US 96/07880
C.(Continua Category	ation) DOCUMENTS CONSIDERED TO BE RELEVANT  Citation of document, with indication, where appropriate, of the relevant passages	
Caugory	chauth of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	BLOOD, vol. 86, no. 9, 1 November 1995, pages 3308-3313, XP000602034 FIBBE W.E. ET AL: "Accelerated reconstitution of platelets and erythrocytes after syngenic transplantation of bone marrow cells derived from thrombopoietin pretreated donor mice" see the whole document	1-17
A	BLOOD, vol. 84, no. 10, 1994, page 242a XP002013272 SPRUGEL K.H. ET AL: "Recombinant thrombopoietin stimulates rapid platelet recovery in thrombocytopenic mice" see abstract 952	1-17
A	NATURE, vol. 369, 1994, LONDON GB, pages 533-538, XP002013273 FREDERIC J. DE SAUVAGE: "Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-MPL ligand" see the whole document	1-17
A	STEM CELLS, vol. 12, no. 1, 1994, pages 91-97, XP002013274 KAUSHANSKY K.: "The mpl ligand: Molecular and cellular biology of the critical regulator of megakaryocyte development" see the whole document	1-17
A	NATURE, vol. 369, 1994, LONDON GB, pages 568-571, XP002013275 KAUSHANSKY K. ET AL: "Promotion of megakaryocyte progenitor expansion and differentiation by the c-MPL ligand thrombopoietin" see the whole document	1-17

1

Form PCT/ISA/218 (continuation of second sheet) (July 1992)

mational application No.

### INTERNATIONAL SEARCH REPORT

PCT/US 96/07880

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: 1-8,13-17 because they relate to subject matter not required to be searched by this Authority, namely: Remark: Although these claims are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the composition.
2. Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searches without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest  The additional search fees were accompanied by the applicant's protest.  No protest accompanied the payment of additional search fees.